Angela Verrecchio’s practice focuses on patent litigation, and also includes patent prosecution, client counseling, due diligence and opinion work. Ms. Verrecchio’s practice encompasses a variety of technologies, including complex biotechnology, chemical inventions, such as monoclonal antibodies, biosimilars, pharmaceuticals, DNA diagnostics and medical devices, such as hemostatic devices, surgical sutures, surgical staplers and blood glucose monitoring devices. Ms. Verrecchio also has significant experience representing clients in ANDA litigations.
Practice & Background
Ms. Verrecchio has significant trial experience. Most recently, she was part of a trial team defending a medical device maker against claims of patent infringement before the ITC. After trial, the case was settled on favorable terms for the client. She was also recently part of the trial team that secured a jury verdict for Janssen in a patent case involving therapeutic antibody technology. The jury returned a verdict for the defendant finding the asserted claims invalid for obviousness, lack of written description and lack of enablement. She was also a member of the trial team that won a $1.67 billion verdict on behalf of Centocor Ortho Biotech, Inc. and New York University, in the Eastern District of Texas. That case involved an infringement suit against Abbott Laboratories for its blockbuster drug Humira®. The jury returned a verdict finding the patent-in-suit willfully infringed and not invalid. Bloomberg reported the $1.67 billion verdict as the largest patent jury verdict in U.S. history. Ms. Verrecchio is also currently representing multiple defendants in ANDA litigation involving a narcotic pharmaceutical product.
Ms. Verrecchio has a solid grounding in science, with a B.S. in biochemistry from the Philadelphia College of Pharmacy and Science (now the University of the Sciences in Philadelphia) and a M.S. in biomedical chemistry from Thomas Jefferson University. While pursuing her graduate degree, Ms. Verrecchio served as a research technician at Thomas Jefferson University’s Cardeza Foundation for Hematologic Research.
She is an active member of the Philadelphia Intellectual Property Law Association and is a former president of the organization.
Ms. Verrecchio’s recent engagements include:
- currently representing innovator pharmaceutical company in patent infringement suit involving monoclonal antibodies, brought under the Biologics Price Competition and Innovation Act (D. Mass.)
- currently representing biotech companies in patent infringement suit involving first ever FDA-approved monoclonal antibody to treat high cholesterol (D. Del.)
- currently representing leading supplier of DNA detection systems in patent infringement suit (D. Del.)
- currently representing pharmaceutical company in defending against claims in multiple ANDA litigations involving oxycodone (S.D.N.Y.)
- represented medical device manufacturer in patent infringement suit in district court and U.S. International Trade Commission; succeeded in obtaining favorable settlements from plaintiff (N.D. Il.; U.S. ITC)
- represented pharmaceutical company in series of patent infringement suits involving monoclonal antibody therapeutics (D. Mass.); succeeded to obtaining district court verdict of invalidity, which was affirmed on appeal
- represented pharmaceutical company in patent infringement suit involving method of using monoclonal antibodies for therapeutic treatment (D. Mass.); succeeded in obtaining favorable settlement for client
- represented pharmaceutical company in challenging biotechnology patent (C.D. Calif.); succeeded in obtaining settlement saving client tens of millions of dollars in royalties.
Awards & Accolades
- recognized by Best Lawyers in America as a leading practitioner in the area of intellectual property litigation in 2014-2016
- named “Rising Star” in the field of intellectual property litigation by Philadelphia magazine in 2008, 2010, 2011 and 2012.
- Structuring and Negotiating Patent Litigation Settlements, Association of Corporate Counsel Greater Philadelphia/Delaware Valley’s Intellectual Property Law CLE Institute, July 15, 2015
- The Objective Prong of Willfulness is a Matter of Law: Bard Peripheral Vascular, Inc. v. W.L. Gore & Assoc., Inc. (Fed. Cir. 2012), 29th Annual Joint Patent Practice Seminar, March 2013
- CAFC Litigation Review, Philadelphia Intellectual Property Law Association’s 26th Annual Review of the Intellectual Property Decisions of the U.S. Court of Appeals for the Federal Circuit, May 2011.